射频消融联合化疗栓塞与单纯射频消融治疗肝细胞癌的系统评价和荟萃分析。
Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis.
机构信息
Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China; Fudan University, Institute of Clinical Epidemiology, School of Public Health, Key Laboratory of Public Health Safety of Ministry of Education, 200032 Shanghai, PR China.
Shanghai Jiaotong University, School of Medicine, Ruijin Hospital, Department of Traditional Chinese Medicine, 200025 Shanghai, PR China.
出版信息
Clin Res Hepatol Gastroenterol. 2016 Jun;40(3):309-314. doi: 10.1016/j.clinre.2015.07.008. Epub 2015 Oct 1.
BACKGROUND
To determine whether the use of radiofrequency ablation (RFA) plus transcatheter arterial chemoembolization (TACE) is more effective than the use of RFA alone for patients with hepatocellular carcinoma (HCC).
METHODS
A computer-based search was performed. Randomised trials comparing RFA plus TACE and RFA alone for treatment of HCC were included in this meta-analysis. The outcome of interest for our analysis was survival (recurrence-free survival and overall survival).
RESULTS
Eight trials with 648 patients were eligible for this meta-analysis. Our pooled results suggest that RFA plus TACE is associated with a significant advantage in recurrence-free survival (RFS) (HR=0.58; 95% CI=0.42-0.80, P=0.001), and overall survival (OS) (HR=0.60; 95% CI=0.47-0.76, P<0.001).
CONCLUSION
TACE combined with RFA was more effective than RFA alone, especially for treatment for intermediate and large-size hepatic tumours or younger patients with HCC.
背景
为了确定射频消融（RFA）联合经导管动脉化疗栓塞（TACE）是否比单独使用 RFA 更有效治疗肝细胞癌（HCC）患者。
方法
进行了计算机检索。本荟萃分析纳入了比较 RFA 联合 TACE 和单独 RFA 治疗 HCC 的随机试验。我们分析的感兴趣结局是生存（无复发生存和总生存）。
结果
共有 8 项试验，共 648 例患者符合条件。我们的汇总结果表明，RFA 联合 TACE 在无复发生存（RFS）（HR=0.58；95%CI=0.42-0.80，P=0.001）和总生存（OS）（HR=0.60；95%CI=0.47-0.76，P<0.001）方面具有显著优势。
结论
TACE 联合 RFA 比单独使用 RFA 更有效，特别是对于治疗中大型肝肿瘤或年轻 HCC 患者。
Zotero 插件